U.S. markets close in 6 hours 27 minutes
  • S&P 500

    3,868.88
    +57.73 (+1.51%)
     
  • Dow 30

    31,400.78
    +468.41 (+1.51%)
     
  • Nasdaq

    13,404.03
    +211.68 (+1.60%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.51
    +0.01 (+0.02%)
     
  • Gold

    1,737.80
    +9.00 (+0.52%)
     
  • Silver

    26.98
    +0.53 (+2.02%)
     
  • EUR/USD

    1.2051
    -0.0036 (-0.30%)
     
  • 10-Yr Bond

    1.4310
    -0.0290 (-1.99%)
     
  • GBP/USD

    1.3926
    +0.0004 (+0.03%)
     
  • USD/JPY

    106.6250
    +0.1230 (+0.12%)
     
  • BTC-USD

    48,214.29
    +3,583.27 (+8.03%)
     
  • CMC Crypto 200

    967.86
    +39.63 (+4.27%)
     
  • FTSE 100

    6,563.27
    +79.84 (+1.23%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Why BofA Is Double Downgrading Cerner: 'Not Much Room For Upside'

  • Oops!
    Something went wrong.
    Please try again later.
Priya Nigam
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Cerner Corporation’s (NASDAQ: CERN) long-term growth is likely to be slightly lower than was earlier anticipated, and there is lack of a “possible novel catalyst” to drive share price appreciation, according to BofA Securities.

The Cerner Analyst: Michael Cherny downgraded Cerner from Buy to Underperform and lowered the price target from $82 to $76.

The Cerner Thesis: The company is still among the market leaders across health IT and electronic health records, Cherny said in a Tuesday downgrade note.

Cerner could sustain growth and leverage its installed base to move into more strategic growth areas “over a multiyear period,” the analyst said. 

Additional contributions from the rollout of the company's Veterans Affairs contract should also support double-digit growth, he said.

These catalysts are already well-understood, and the next opportunity for upside is unclear “given the maturity of the traditional core business and the longer-dated potential contribution from the newer growth opportunities,” Cherny said. 

“Additionally, we see CERN’s valuation as not necessarily stretched but also not leaving much room for upside vs. its multi-year average. We do not foresee meaningful stock downside from here but also do not have enough upside to warrant a more constructive stance.”

CERN Price Action: Shares of Cerner were down by 0.94% at $79.46 at last check. 

Cerner headquarters. Photo by Americasroof via Wikimedia

Latest Ratings for CERN

Jan 2021

B of A Securities

Downgrades

Buy

Underperform

Oct 2020

Deutsche Bank

Maintains

Buy

Oct 2020

Wells Fargo

Maintains

Overweight

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.